Elanco Animal Health (NYSE:ELAN) Shares Sold by Cypress Asset Management Inc. TX

Cypress Asset Management Inc. TX cut its position in Elanco Animal Health (NYSE:ELAN) by 5.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,849 shares of the company’s stock after selling 2,907 shares during the period. Cypress Asset Management Inc. TX’s holdings in Elanco Animal Health were worth $1,325,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its holdings in Elanco Animal Health by 9.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 42,332,541 shares of the company’s stock worth $1,430,840,000 after acquiring an additional 3,653,638 shares during the period. Vanguard Group Inc. grew its holdings in Elanco Animal Health by 10.2% during the second quarter. Vanguard Group Inc. now owns 31,942,263 shares of the company’s stock worth $1,079,649,000 after acquiring an additional 2,955,748 shares during the period. Primecap Management Co. CA grew its holdings in Elanco Animal Health by 0.3% during the second quarter. Primecap Management Co. CA now owns 30,708,116 shares of the company’s stock worth $1,037,934,000 after acquiring an additional 100,210 shares during the period. BlackRock Inc. grew its holdings in Elanco Animal Health by 4.7% during the second quarter. BlackRock Inc. now owns 20,483,172 shares of the company’s stock worth $692,331,000 after acquiring an additional 924,059 shares during the period. Finally, Morgan Stanley grew its holdings in Elanco Animal Health by 18.5% during the second quarter. Morgan Stanley now owns 13,019,824 shares of the company’s stock worth $440,071,000 after acquiring an additional 2,034,373 shares during the period.

Several analysts recently commented on ELAN shares. UBS Group raised Elanco Animal Health from a “sell” rating to a “neutral” rating and dropped their target price for the stock from $31.00 to $30.00 in a report on Thursday, August 15th. Zacks Investment Research lowered Elanco Animal Health from a “hold” rating to a “sell” rating in a report on Tuesday, October 15th. Goldman Sachs Group started coverage on Elanco Animal Health in a report on Monday, September 9th. They issued a “positive” rating on the stock. They noted that the move was a valuation call. Bank of America lowered Elanco Animal Health from a “buy” rating to a “neutral” rating and set a $30.00 price objective on the stock. in a report on Monday, August 26th. Finally, Barclays started coverage on Elanco Animal Health in a report on Monday, September 23rd. They issued an “overweight” rating and a $36.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the stock. Elanco Animal Health currently has a consensus rating of “Hold” and an average target price of $33.63.

In other news, Director Deborah Turner Kochevar bought 1,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were acquired at an average price of $27.95 per share, for a total transaction of $27,950.00. Also, insider Todd S. Young bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average price of $26.57 per share, for a total transaction of $265,700.00. Following the transaction, the insider now owns 28,883 shares of the company’s stock, valued at $767,421.31. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 1,497,497 shares of company stock worth $4,457,115. Company insiders own 0.04% of the company’s stock.

ELAN traded down $0.15 during trading on Monday, hitting $26.08. The company’s stock had a trading volume of 7,910 shares, compared to its average volume of 3,964,141. The company has a current ratio of 3.07, a quick ratio of 1.71 and a debt-to-equity ratio of 0.45. Elanco Animal Health has a twelve month low of $25.51 and a twelve month high of $35.46. The business’s fifty day simple moving average is $27.03 and its 200 day simple moving average is $30.86. The firm has a market capitalization of $9.57 billion and a price-to-earnings ratio of 22.17.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.26 by $0.02. Elanco Animal Health had a return on equity of 7.83% and a net margin of 4.69%. The company had revenue of $781.60 million for the quarter, compared to analyst estimates of $781.49 million. Elanco Animal Health’s revenue was up 1.5% on a year-over-year basis. As a group, equities research analysts forecast that Elanco Animal Health will post 1.08 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Featured Story: What is the definition of market timing?

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.